Skip to main content

Table 2 Hepatic adverse effects among 81MM patients

From: The clinical impact of hepatitis C virus infection in Egyptian multiple myeloma patients

Items No. of patients (%) P value
Ab (-)ve n = 66 (81.5%) Ab (+)ve/PCR (-)ve n = 9 (11.1%) Ab (+)ve/PCR (+)ve n = 6 (7.4%)
Child-Pugh score (patients)
 A 47 (71.2%) 4 (44.4%) 5 (83.3%) 0.195
 B 19 (18.8%) 5 (55.6%) 1 (16.7%)
ALT increase
 Grade 0 65 (98.4%) 9 (100.0%) 6 (100.0%) 0.885
 Grade 1 0 (0.0%) 0 (0.0%) 0 (0.0%)
 Grade 2 0 (0.0%) 0 (0.0%) 0 (0.0%)
 Grade 3 1 (1.6%) 0 (0.0%) 0 (0.0%)
AST increase
 Grade 0 57 (86.4%) 6 (66.7%) 3 (50.0%) 0.222
 Grade 1 7 (10.6%) 3 (33.3%) 2 (33.3%)
 Grade 2 1 (1.5%) 0 (0.0%) 1 (16.7%)
 Grade 3 1 (1.5%) 0 (0.0%) 0 (0.0%)
Total bil. increase
 Grade 0 56 (85%) 5 (55.6%) 4 (66.7%) 0.005*
 Grade 1 3 (4.5%) 4 (44.4%) 1 (16.7%)
 Grade 2 3 (4.5%) 0 (0.0%) 0 (0.0%)
 Grade 3 3 (4.5%) 0 (0.0%) 0 (0.0%)
 Grade 4 1 (1.5%) 0 (0.0%) 1 (16.7%)
  1. HCV hepatitis C virus, ALT alanine transaminase, AST aspartate aminotransferase, T.bil total bilirubin
  2. *Significant at p ≤ 0.05